Atopic Dermatitis: Where Are We?

Atopic dermatitis (AD), also known as eczema, is one of the most common inflammatory skin disorders worldwide, with an increasing incidence in the last few decades, especially in developed countries. In recent years, the underlying molecular basis for AD has been increasingly characterized, particularly surrounding barrier dysfunction, cutaneous and systemic immune abnormalities, and the role of the microbiome. This has led to the development of new targeted therapies and improved treatment methods for this challenging disease.

ALLEVIATE Atopic Dermatitis: Cutting-Edge CME

Our ALLEVIATE Atopic Dermatitis Initiative is an online CME tool that aims to provide clinicians with new strategies to improve standards of care for AD. Our goals are multifold:

  1. Describe pathophysiological findings that have informed the selection of new therapeutic targets.
  2. Identify best practices for assessment and diagnosis of AD in adults, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden.
  3. Review the clinical profiles and mechanisms of action of emerging agents for AD treatment.
  4. Explain how comorbidities and barriers to adherence play a role in treatment choice.
  5. Discuss patient-centered health care management teams and the respective roles of each team member.

Thank you for visiting us today. We welcome you to our website and invite you to explore the link below for information on AD for clinicians and patients.

Enjoy!

mlg-logos
Scroll to Top